Sanofi Obtains FDA Breakthrough Therapy Designation for Anemia Treatment
MT Newswires Live
Feb 09
Sanofi (SNY) said Monday the US Food and Drug Administration granted Breakthrough Therapy designation to rilzabrutinib, an oral Bruton's tyrosine kinase inhibitor, for the treatment of warm autoimmune hemolytic anemia.
The Japanese Ministry of Health, Labour and Welfare also awarded the drug orphan designation for the same rare autoimmune condition, the drugmaker said.
These regulatory statuses are based on safety and efficacy results from the phase 2b and phase 3 Lumina clinical trial, Sanofi said.
The drug obtained an orphan drug designation in other regions for IgG4 disease and sickle cell disease, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.